What is the 20-year outlook for the life sciences industry in New York City? That’s the topic of our first public event in NYC: Life Sciences 2031.
We have a great panel of experts from across the industry lined up for what’s sure to be a lively discussion. They are: Barbara Dalton, VP of venture capital for Pfizer’s Worldwide Business Development and Innovation unit; Sam Isaly, managing partner of OrbiMed Advisors; Eric Schadt, chairman of Mount Sinai Medical School’s department of genetics and genomic sciences and chief scientific officer of Pacific Biosciences; and Samuel Waksal, CEO of Kadmon. Our moderator is Les Funtleyder, portfolio manager of the Miller Tabak Health Care Transformation Fund.
There are still seats available, including discounted admissions for startups and students. Register here. And catch us on Twitter at #NY2031.